结直肠癌免疫治疗中DDR基因突变预后数据表
结直肠癌免疫治疗患者DDR基因突变数据及预后分析,揭示DDR突变作为潜在生物标志物。

基本信息
资源简介
结直肠癌免疫治疗中DDR基因突变预后数据表
【一句话概览】
本数据集是 figshare 公开的组学数据集,收录 1 个文件、合计 14.45 KB,主题涵盖 DNA damage repair (DDR)、immune checkpoint inhibitor (ICI)、colorectal cancer (CRC)、biomarker、microsatellite instability,可用于生物标志物发现与分子分型研究,CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《DataSheet_1_DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.docx》。配套论文《Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.》发表于 Journal of Clinical Oncology(2015),DOI:10.1200/jco.2015.33.15_suppl.3001。源站首次发布:2021-02-19。
【数据内容】
源站原始描述:BackgroundDNA damage repair (DDR) genes were recently implicated in the anti-tumor immune response. Therefore, it is worthwhile to unravel the implications of DDR pathways in the shaping of immune responsiveness in colorectal cancer (CRC) patients receiving immune checkpoint inhibitors (ICI). MethodsWe analyzed publicly available genomic data from a cohort treated with ICI from Memorial Sloan Kettering Cancer Center (MSK ICI cohort). To characterize the impact of the DDR mutation, the genomic da…
【数据结构与技术规格】
文件数 1 个,合计 14.45 KB。DataSheet_1_DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.docx:application/zip,14.45 KB。数据集 DOI:10.3389/fonc.2020.549777.s001。
【主题与分类】
源站学科分类:Cancer、Haematological Tumours、Radiation Therapy、Solid Tumours、Oncology and Carcinogenesis not elsewhere classified、Molecular Targets。主题标签:DNA damage repair (DDR)、immune checkpoint inhibitor (ICI)、colorectal cancer (CRC)、biomarker、microsatellite instability。
【适用方向】
组学数据适用于生物标志物发现与分子分型相关建模研究。
【获取与许可】
源站页面:https://frontiersin.figshare.com/articles/dataset/DataSheet_1_DNA_Damage_Repair_Gene_Mutations_Are_Indicative_of_a_Favorable_Prognosis_in_Colorectal_Cancer_Treated_With_Immune_Checkpoint_Inhibitors_docx/14061575
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Song, Yipeng; Huang, Jian; Liang, Dandan; Hu, Ying; Mao, Beibei; Li, Qiujing; et al. (2021). DataSheet_1_DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.docx. Frontiers. Dataset
【使用注意】
· 源站最后修改于 2023-06-01,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:DataSheet_1_DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.docx
- DOI:10.3389/fonc.2020.549777.s001
- 发布日期:2021-02-19
- 文件数:1 个
- 文件总体积:14.45 KB
- 源站页面:https://frontiersin.figshare.com/articles/dataset/DataSheet_1_DNA_Damage_Repair_Gene_Mutations_Are_Indicative_of_a_Favorable_Prognosis_in_Colorectal_Cancer_Treated_With_Immune_Checkpoint_Inhibitors_docx/14061575
命令行下载
curl -L -o "DataSheet_1_DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.docx" "https://ndownloader.figshare.com/files/26542268"
文件清单
DataSheet_1_DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.docx(14.45 KB)
文件总体积 14.45 KB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
BackgroundDNA damage repair (DDR) genes were recently implicated in the anti-tumor immune response. Therefore, it is worthwhile to unravel the implications of DDR pathways in the shaping of immune responsiveness in colorectal cancer (CRC) patients receiving immune checkpoint inhibitors (ICI).
MethodsWe analyzed publicly available genomic data from a cohort treated with ICI from Memorial Sloan Kettering Cancer Center (MSK ICI cohort). To characterize the impact of the DDR mutation, the genomic data of The Cancer Genome Atlas (TCGA) colorectal adenocarcinoma (COADREAD) dataset was explored. We also analyzed the incidence of DDR mutation and microsatellite instability-high (MSI-H) in a Chinese CRC cohort using panel sequencing.
ResultsThe DDR pathway was commonly mutated (21.8%) in the multicancer MSK ICI cohort, with the highest frequency of 36.4% in CRCs. Survival analysis showed that DDR mutation correlated with an improved overall survival (OS) in CRCs and pan-cancer in the MSK ICI cohort. However, no significant associations were identified in the TCGA COADREAD and MSK non-ICI CRCs. DDR mutation was associated with higher tumor mutational burden (TMB) levels and increased immune cell infiltration and immune checkpoint molecule expression in the TCGA COADREAD dataset. Last, we investigated the DDR mutational pattern and its associations with MSI-H and other genomic features in a Chinese CRC cohort. Notably, MSI-H and DDR mutation was present in 5.7% and 13.4% of cases, respectively, which suggests that DDR identifies a higher proportion of potential responders than MSI-H.
ConclusionOur data suggest that DDR mutation as an indication of enhanced cancer immunity, and it may function as a biomarker for patients with CRCs receiving ICI treatment. The high incidence of DDR mutation in the Chinese CRC cohort emphasizes the future utility of panel-based DDR evaluation in guiding ICI treatment.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fonc.2020.549777.s001(source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_DNA_Damage_Repair_Gene_Mutations_Are_Indicative_of_a_Favorable_Prognosis_in_Colorectal_Cancer_Treated_With_Immune_Checkpoint_Inhibitors_docx/14061575)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




